Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens

Journal of Clinical Oncology

Volumn 26, Issue 32, 2008, Pages 5233-5239

  Dudley, Mark E ^a   Yang, James C ^a   Sherry, Richard ^a   Hughes, Marybeth S ^a   Royal, Richard ^a   Kammula, Udai ^a   Robbins, Paul F ^a   Huang, JianPing ^a   Citrin, Deborah E ^a   Leitman, Susan F ^a   Wunderlich, John ^a   Restifo, Nicholas P ^a   Thomasian, Armen ^a   Downey, Stephanie G ^a   Smith, Franz O ^a   Klapper, Jacob ^a   Morton, Kathleen ^a   Laurencot, Carolyn ^a   White, Donald E ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DIAZOXIDE; FLUDARABINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; SILDENAFIL; STEROID; SULFAMETHOXAZOLE; TRIMETHOPRIM; VALACICLOVIR;

ADOLESCENT; ADOPTIVE CELL THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CELL THERAPY; CELL TRANSFER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LYMPHOCYTE DEPLETION; MALE; MELANOMA; PRIORITY JOURNAL; PULMONARY VENO-OCCLUSIVE DISEASE; TUMOR ASSOCIATED LEUKOCYTE; UVEITIS; WHOLE BODY RADIATION;

ADOLESCENT; ADOPTIVE TRANSFER; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; CHEMOTHERAPY, ADJUVANT; CHILD; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; KAPLAN-MEIERS ESTIMATE; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PILOT PROJECTS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; TIME FACTORS; TREATMENT OUTCOME; VIDARABINE;

EID: 55949125601     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.5449     Document Type: Article

References (18)

1. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 351:998-1012, 2004
2. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002
3. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357, 2005
4. Zippelius A, Batard P, Rubio-Godoy V, et al: Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res 64:2865-2873, 2004
5. Topalian SL, Muul LM, Solomon D, et al: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102:127-141, 1987
6. Dudley ME, Wunderlich J, Nishimura MI, et al: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363-373, 2001
7. Riddell SR, Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128:189-201, 1990
8. Antony PA, Piccirillo CA, Akpinarli A, et al: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591-2601, 2005
9. Gattinoni L, Finkelstein SE, Klebanoff CA, et al: Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202:907-912, 2005
10. Paulos CM, Wrzesinski C, Kaiser A, et al: Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 117:2197-2204, 2007
11. Muranski P, Boni A, Wrzesinski C, et al: Increased intensity lymphodepletion and adoptive immunotherapy: How far can we go? Nat Clin Pract Oncol 3:668-681, 2006
12. Wrzesinski C, Paulos CM, Gattinoni L, et al: Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest 117:492-501, 2007
13. Dudley ME, Wunderlich JR, Shelton TE, et al: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342, 2003
14. Zhou J, Shen X, Huang J, et al: Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 175:7046-7052, 2005
15. Schwartzentruber DJ: Guidelines for the safe administration of high-dose interleukin-2. J Immunother 24:287-293, 2001
16. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10:909-915, 2004
17. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor- infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994
18. Wrzesinski C, Restifo NP: Less is more: Lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based antitumor immunotherapy. Curr Opin Immunol 17:195-201, 2005